GlassScriptPhysician profile
Joseph Barak
NPI 1134390735
$4,651.21
in general payments reported to CMS, 2019-2025
25 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $99.29 · 2021: $1,233 · 2022: $295 · 2023: $244 · 2024: $589 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,855.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,036.84 | 2019-2025 | Puraply Wound Matrix, Apligraf, Affinity |
| Treace Medical Concepts, INC. | $962.04 | 2021 | |
| Arthrosurface Incorporated | $942.26 | 2019 | |
| Kerecis Limited | $304.10 | 2022-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Smith+Nephew, INC. | $303.14 | 2019-2025 | Renasys Go V2 Home, Pico 7, Renasys Touch |
| Convatec INC. | $191.69 | 2024-2025 | |
| Integra Lifesciences Corporation | $144.92 | 2022-2024 | Tcc-Ez, Tenoglide |
| Paratek Pharmaceuticals, INC. | $109.68 | 2020-2025 | Nuzyra |
| Stryker Corporation | $87.08 | 2019-2025 | Ortholoc 3di, Phalinx, Dart-Fire |
| Melinta Therapeutics, LLC | $76.30 | 2019 | |
| Solventum Corporation | $70.17 | 2024-2025 | Activ.A.C. |
| Mimedx Group, INC. | $61.79 | 2025 | |
| Kci USA, INC. | $49.96 | 2019-2023 | Activ.A.C. |
| Horizon Therapeutics Plc | $39.77 | 2020-2021 | |
| Ibsa Pharma INC. | $34.00 | 2023 | Tirosint, Licart |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $33.70 | 2019-2021 | |
| Dynasplint Systems INC. | $32.54 | 2025 | Dynasplint |
| Nabriva Therapeutics, Plc | $30.30 | 2021 | |
| Biowound Solutions, INC. | $27.85 | 2025 | Bio-Connekt |
| Nevro Corp. | $27.74 | 2023-2024 | Senza |
| Alfasigma USA, INC. | $24.48 | 2021 | |
| Djo, LLC | $20.99 | 2025 | Cmf |
| Triad Life Sciences INC. | $15.16 | 2022 | |
| Acell, INC. | $13.67 | 2019 | |
| Bioventus LLC | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Barak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.